Last reviewed · How we verify
OCR
OCR is an oral contraceptive containing ethinylestradiol and norgestimate that prevents pregnancy by suppressing ovulation and altering cervical mucus.
OCR is an oral contraceptive containing ethinylestradiol and norgestimate that prevents pregnancy by suppressing ovulation and altering cervical mucus. Used for Contraception, Acne vulgaris (in females), Menorrhagia / heavy menstrual bleeding.
At a glance
| Generic name | OCR |
|---|---|
| Also known as | RO4964913, PRO70769, rhuMAb 2H7 |
| Sponsor | Hoffmann-La Roche |
| Drug class | Combined oral contraceptive |
| Target | Estrogen receptor and progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
OCR works through combined hormonal contraception: the estrogen component suppresses follicle-stimulating hormone (FSH) to prevent follicle development, while the progestin inhibits luteinizing hormone (LH) surge to prevent ovulation. Additionally, the progestin thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Approved indications
- Contraception
- Acne vulgaris (moderate)
- Menorrhagia / heavy menstrual bleeding
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis (PHASE4)
- A Privacy-Preserving OCR-LLM System for Coronary Syndrome Subtyping From Admission HPI: Multicenter Validation in China and the US
- Digital Remote Management for Care and Continuous Optimization Versus Usual Care to Reduce Risk of Atherosclerotic Cardiovascular Diseases (DigiCare-ASCVD) (NA)
- Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD) (NA)
- Optimization of Medical Time in the Emergency Department: Impact of an AI-Based System on Prescription Entry (NA)
- Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease (NA)
- Different Peribulbar Blocks With SPI-guided Anaesthesia for VRS (P&MSPIVRS) (NA)
- Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |